First Time Loading...

Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 2.65 USD -5.36% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

CDXS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. [ Read More ]

The intrinsic value of one CDXS stock under the Base Case scenario is 3.69 USD. Compared to the current market price of 2.65 USD, Codexis Inc is Undervalued by 28%.

Key Points:
CDXS Intrinsic Value
Base Case
3.69 USD
Undervaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Codexis Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CDXS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Codexis Inc

Provide an overview of the primary business activities
of Codexis Inc.

What unique competitive advantages
does Codexis Inc hold over its rivals?

What risks and challenges
does Codexis Inc face in the near future?

Has there been any significant insider trading activity
in Codexis Inc recently?

Summarize the latest earnings call
of Codexis Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Codexis Inc.

Provide P/S
for Codexis Inc.

Provide P/E
for Codexis Inc.

Provide P/OCF
for Codexis Inc.

Provide P/FCFE
for Codexis Inc.

Provide P/B
for Codexis Inc.

Provide EV/S
for Codexis Inc.

Provide EV/GP
for Codexis Inc.

Provide EV/EBITDA
for Codexis Inc.

Provide EV/EBIT
for Codexis Inc.

Provide EV/OCF
for Codexis Inc.

Provide EV/FCFF
for Codexis Inc.

Provide EV/IC
for Codexis Inc.

Show me price targets
for Codexis Inc made by professional analysts.

What are the Revenue projections
for Codexis Inc?

How accurate were the past Revenue estimates
for Codexis Inc?

What are the Net Income projections
for Codexis Inc?

How accurate were the past Net Income estimates
for Codexis Inc?

What are the EPS projections
for Codexis Inc?

How accurate were the past EPS estimates
for Codexis Inc?

What are the EBIT projections
for Codexis Inc?

How accurate were the past EBIT estimates
for Codexis Inc?

Compare the revenue forecasts
for Codexis Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Codexis Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Codexis Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Codexis Inc compared to its peers.

Compare the P/E ratios
of Codexis Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Codexis Inc with its peers.

Analyze the financial leverage
of Codexis Inc compared to its main competitors.

Show all profitability ratios
for Codexis Inc.

Provide ROE
for Codexis Inc.

Provide ROA
for Codexis Inc.

Provide ROIC
for Codexis Inc.

Provide ROCE
for Codexis Inc.

Provide Gross Margin
for Codexis Inc.

Provide Operating Margin
for Codexis Inc.

Provide Net Margin
for Codexis Inc.

Provide FCF Margin
for Codexis Inc.

Show all solvency ratios
for Codexis Inc.

Provide D/E Ratio
for Codexis Inc.

Provide D/A Ratio
for Codexis Inc.

Provide Interest Coverage Ratio
for Codexis Inc.

Provide Altman Z-Score Ratio
for Codexis Inc.

Provide Quick Ratio
for Codexis Inc.

Provide Current Ratio
for Codexis Inc.

Provide Cash Ratio
for Codexis Inc.

What is the historical Revenue growth
over the last 5 years for Codexis Inc?

What is the historical Net Income growth
over the last 5 years for Codexis Inc?

What is the current Free Cash Flow
of Codexis Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Codexis Inc.

Financials

Balance Sheet Decomposition
Codexis Inc

Current Assets 93.5m
Cash & Short-Term Investments 65.1m
Receivables 19.9m
Other Current Assets 8.4m
Non-Current Assets 43.1m
Long-Term Investments 9.7m
PP&E 28.6m
Intangibles 2.5m
Other Non-Current Assets 2.3m
Current Liabilities 35.8m
Accounts Payable 5.9m
Accrued Liabilities 19.8m
Other Current Liabilities 10.1m
Non-Current Liabilities 14.1m
Other Non-Current Liabilities 14.1m
Efficiency

Earnings Waterfall
Codexis Inc

Revenue
70.1m USD
Cost of Revenue
-12.8m USD
Gross Profit
57.3m USD
Operating Expenses
-112.1m USD
Operating Income
-54.8m USD
Other Expenses
-21.4m USD
Net Income
-76.2m USD

Free Cash Flow Analysis
Codexis Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CDXS Profitability Score
Profitability Due Diligence

Codexis Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Declining ROIC
18/100
Profitability
Score

Codexis Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

CDXS Solvency Score
Solvency Due Diligence

Codexis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
43/100
Solvency
Score

Codexis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CDXS Price Targets Summary
Codexis Inc

Wall Street analysts forecast CDXS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CDXS is 6.7 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

Lowest
Price Target
3.03 USD
14% Upside
Average
Price Target
6.7 USD
153% Upside
Highest
Price Target
10.5 USD
296% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CDXS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CDXS Price
Codexis Inc

1M 1M
-23%
6M 6M
+62%
1Y 1Y
-33%
3Y 3Y
-89%
5Y 5Y
-86%
10Y 10Y
+53%
Annual Price Range
2.65
52w Low
1.5
52w High
4.65
Price Metrics
Average Annual Return -5.02%
Standard Deviation of Annual Returns 59.78%
Max Drawdown -96%
Shares Statistics
Market Capitalization 185.2m USD
Shares Outstanding 70 303 600
Percentage of Shares Shorted 3.46%

CDXS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Codexis Inc Logo
Codexis Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

185.2m USD

Dividend Yield

0%

Description

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

Contact

CALIFORNIA
Redwood City
200 Penobscot Dr
+16504218100.0
https://www.codexis.com/

IPO

2010-04-22

Employees

261

Officers

President, CEO & Director
Dr. Stephen George Dilly MBBS, Ph.D.
Chief Operating Officer
Mr. Kevin Norrett M.B.A., M.S.
Chief Legal and Compliance Officer, General Counsel & Secretary
Ms. Margaret Fitzgerald J.D.
Chief Financial Officer
Mr. Sriram Ryali M.B.A.
Director of Investor Relations
Carrie McKim
Senior VP & Head of Human Resources
Ms. Karen Frechou-Armijo
Show More
Senior Vice President of Research
Dr. Stefan Lutz Ph.D.
Senior Vice President of Pharmaceutical Development, Quality & Regulatory
Mr. Robert Sato M.B.A., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CDXS stock?

The intrinsic value of one CDXS stock under the Base Case scenario is 3.69 USD.

Is CDXS stock undervalued or overvalued?

Compared to the current market price of 2.65 USD, Codexis Inc is Undervalued by 28%.